Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst sentiment is moderately positive: Nine brokerages give Eupraxia Pharmaceuticals an average “Moderate Buy” rating, with a consensus 12-month price target of $18.00 versus the stock’s recent price of $6.40.
• The stock remains financially unprofitable and volatile: EPRX has a 52-week range of $5.04 to $9.32 and reported a quarterly loss of $0.23 per share, slightly worse than analysts’ expectations.
• Institutional interest has increased: Several hedge funds opened positions during the first quarter, while Affinity Asset Advisors expanded its holdings by 429.7%, bringing its position to roughly 1.59 million shares.

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) have received an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $18.00.

A number of brokerages recently commented on EPRX. Oppenheimer initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, June 25th. They set an "outperform" rating and a $17.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They issued a "buy" rating and a $25.00 target price for the company. Zacks Research upgraded Eupraxia Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Thursday, May 7th. Cantor Fitzgerald reissued an "overweight" rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, July 15th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research note on Friday, July 17th.

Eupraxia Pharmaceuticals Price Performance

NASDAQ EPRX opened at $6.40 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. The stock has a market cap of $416.12 million, a price-to-earnings ratio of -6.10 and a beta of 1.05. The business has a 50 day simple moving average of $6.47 and a 200 day simple moving average of $7.28. Eupraxia Pharmaceuticals has a 52-week low of $5.04 and a 52-week high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.01). Analysts anticipate that Eupraxia Pharmaceuticals will post -0.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of EPRX. Redmile Group LLC acquired a new position in Eupraxia Pharmaceuticals during the 1st quarter worth approximately $5,068,000. Seven Fleet Capital Management LP bought a new position in shares of Eupraxia Pharmaceuticals during the 1st quarter worth approximately $5,137,000. Rubric Capital Management LP acquired a new stake in shares of Eupraxia Pharmaceuticals in the first quarter valued at approximately $5,004,000. Affinity Asset Advisors LLC raised its holdings in shares of Eupraxia Pharmaceuticals by 429.7% in the first quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company's stock valued at $11,504,000 after purchasing an additional 1,289,005 shares during the last quarter. Finally, DV Trading LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the first quarter worth $1,998,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc NASDAQ: EPRX is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company's core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source